Summary by Moomoo AI
On March 28, 2024, Femasys Inc., a biomedical company specializing in women's healthcare solutions, announced its financial results for the fiscal year ending December 31, 2023. The announcement, which was made in a press release furnished as Exhibit 99.1 to the Current Report on Form 8-K, highlighted several key developments and financial metrics. The company reported a net loss of $14.2 million, or $0.93 per share, compared to the previous year's net loss of $11.4 million, or $0.96 per share. Despite an increase in research and development expenses to $7.2 million, sales decreased slightly to $1.07 million. Femasys ended the year with $21.7 million in cash and cash equivalents and expects these funds to sustain operations into the second half of 2025. The report also included updates on the company's...Show More